



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Application No. 09/857,719

Filed: December 3, 2001

Confirmation No. 9622

For: GENE THERAPY FOR
CARDIOMYOPATHY

Examiner: Q. Janice Li

Art Unit: 1632

Attorney Reference No. 6235-59216-01

MAIL STOP ISSUE FEE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP ISSUE FEE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Date Mailed July 21, 2005

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(e)

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language and one non-English-language document. The relevance of the non-English-language document is described in the English-language translation attached thereto. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being filed after the date of either a final action or, a notice of allowance, and concurrent with payment of the issue fee.

As to the Foreign Medical Sciences Section of Pathophysiology and Clinical Medicine, 19(3), 182-4, 1999 reference, a statement is provided in compliance with 37 C.F.R. § 1.97(e)(1).

As to the Sawa et al. and Aoki et al. references, a statement is provided in compliance with 37 C.F.R. § 1.97(e)(2).


Submitted herewith is a check for \$180.00 to cover the fee as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

	Attorney Docket Number	6235-59216-01
	Application Number	09/857,719
	Filing Date	December 3, 2001
	First Named Inventor	Morishita
	Art Unit	1632
	Examiner Name	Q. Janice Li

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		"Transgenic Methods in the Gene Therapy for Cardiac Diseases," <i>Foreign Medical Sciences Section of Pathophysiology and Clinical Medicine</i> , 19(3), 182-184 (1999).
		Aoki et al., "Efficient <i>in vivo</i> Gene Transfer into the Heart in the Rat Myocardial Infarction Model Using the HVJ (Hemagglutinating Virus of Japan)-Liposome Method," <i>J. Mol. Cell. Cardiol.</i> 29:949-959 (1997).
		Sawa et al., "Efficient Gene Transfer Method into the Whole Heart Through the Coronary Artery with Hemagglutinating Virus of Japan Liposome," <i>J. Thorac. Cardiovasc. Surg.</i> 113:512-519 (1997).

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



WPN:SLR 07/21/05 6235-59216-01 197c1 statement.doc MEID-A0101P-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Morishita et al.

Application No. 09/857,719

Filed: December 3, 2001

Confirmation No. 9622

For: GENE THERAPY FOR
CARDIOMYOPATHY

Examiner: Q. Janice Li

Art Unit: 1632

Attorney Reference No. 6235-59216-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)


Date Mailed July 21, 2005

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

STATEMENT PURSUANT TO 37 C.F.R. § 1.97(e)(1)

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1).

I hereby state that the Foreign Medical Sciences Section of Pathophysiology and Clinical Medicine, 19(3), 182-4, 1999 reference contained in the Information Disclosure Statement (IDS) filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.



Name: Noriko Suto Ph.D.

July 21, 2005

Date: